Brief: Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide
10/11/2023 13:36
Nov 10 (Reuters) - Sagimet Biosciences Inc SGMT.O :
* SAGIMET BIOSCIENCES PRESENTS PRECLINICAL RESULTS
SUPPORTING THE
THERAPEUTIC POTENTIAL OF ITS FASN INHIBITOR IN COMBINATION WITH
SEMAGLUTIDE AND A COMPREHENSIVE LIPIDOMIC ANALYSIS OF INTERIM
FASCINATE-2 DATA AT AASLD - THE LIVER MEETING® 2023
* SAGIMET BIOSCIENCES INC: COMBINATION TREATMENT OF A FASN
INHIBITOR WITH SEMAGLUTID IMPROVED SEVERAL BIOMARKERS ASSOCIATED
WITH NASH IN A MOUSE MODEL
* SAGIMET BIOSCIENCES INC - ON TRACK TO REPORT TOPLINE
RESULTS OF
FASCINATE-2 PHASE 2B CLINICAL TRIAL, INCLUDING BIOPSY DATA, IN
Q1 OF NEXT YEAR
* SAGIMET BIOSCIENCES: DATA SUGGESTS THAT GLP-1 THERAPY
ALONE IS
ASSOCIATED WITH MAJOR BODY WEIGHT LOSS BUT DOES NOT
SIGNIFICANTLY REDUCE LIVER FIBROSIS
* SAGIMET BIOSCIENCES INC: RESULTS SUPPORT FURTHER CLINICAL
EVALUATION OF DENIFANSTAT IN COMBINATION WITH GLP-1 RECEPTOR
AGONISTS
Source text for Eikon: ID:nGNX1bG1FZ
Further company coverage: SGMT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sagimet Biosciences
See all newsBrief: Sagimet Biosciences Announces Pricing Of $115.0 Million Underwritten Offering Of Series A Common Stock And Pre-Funded Warrants
Brief: Sagimet Biosciences - Suspends And Terminates ATM Prospectus Supplement For Series A Common Stock Effective Sept 30
Brief: Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial Of Denifanstat In Acne Toward Patient Enrollment In Q4 2026
Brief: Sagimet Biosciences Phase 3 Clinical Trial Is On Track To Initiate In Second Half Of 2026
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage